Celera releases Applera for AB sale
- 04 July, 2008 12:43
- Comments
US equipment giant Celera has formally separated from its Applera business to allow the sale of Applera's Applied Biosystems brand to Invitrogen.
The Invitrogen purchase, announced two weeks ago, is worth AU$7 billion in cash and stocks.
Celera will now operate as an independent healthcare company, with a focus on personalising disease management, according to Celera president and CEO Kathy Ordones.
Applied Biosystems is a global leader in genetic sequencing and analysis technology.
Invitrogen, another global giant in laboratory equipment, is predicting that the merged corporation, which will specialise in the areas of genetic analysis, proteomics, cell biology and cell systems, will generate nearly AU$3.7 billion in annual sales.
The company's corporate headquarters will be located in Carlsbad, California.
The chairman and CEO of the company will be Gregory T. Lucier, and Mark P. Stevenson will become president and COO.
Applera shareholders will receive $38.00 per share.
-
Fluorescence Applications in Biotechnology and Life Sciences
-
The Scientific American a Day in the Life of Your Brain
-
Introduction to Statistics for Forensic Scientists
-
Dictionary of DNA and Genome Technology 2E
-
Writing Scientific Research Articles - Strategy and Steps
-
An Introduction to Molecular Biotechnology - Molecular Fundamentals, Methods and Applications in Modern Biotechnology
-
Proteins - Structure and Function
-
Molecular Forensics
-
Statistics for Terrified Biologists
Comments
Post new comment